drugset / Trial / NCT06251947
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
Phase 2
Recruiting
83 enrolled
Shandong University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).
Timeline
- Start
- 2024-04-15
- Primary completion
- 2026-06
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | F-627 | Protein / enzyme biologic | 20 mg | Subcutaneous |